Prices dropped, prescriptions rose in 2018 -- but it's still not a clear track
The landmark ODYSSEY Outcomes trial reported last March showed a hard clinical outcomes advantage and all-cause mortality reduction with alirocumab (Praluent). You can read MedPage Today's summary here. In this follow-up we examine how the trial has affected practice since then.